Yet another new COVID booster has recently been approved by the TGA. Here’s what to know about the JN.1 shot.
Articles on JN.1
Displaying all articles
The TGA is considering an updated COVID vaccine, which would be better matched to current variants.
Emerging evidence suggests LB.1 could be more transmissible than earlier Omicron subvariants, but there’s nothing to suggest it will cause more severe disease.
On the fourth anniversary of New Zealand’s first COVID case it’s clear this is not a normal pandemic. Despite fatigue and indifference, New Zealand must heed the evidence and improve its response.
The JN.1 variant has become dominant in Australia and around the world, causing large waves of infections. Here’s what we know about it so far – and why it’s so important.
Another year, another COVID wave. Here’s what we know about what the virus is doing around the country.
Top contributors
-
Professor of Biostatistics and Epidemiology, Adelaide University
-
Professor of Public Health, University of Otago
-
Associate Professor, Immunovirology and Pathogenesis Program, Kirby Institute, UNSW
-
Research Associate Professor of Public Health, University of Otago
-
Director and CEO, Burnet Institute
-
Associate Professor of Health Science, University of Auckland, Waipapa Taumata Rau
-
Senior Research and Policy Officer, Burnet Institute
-
Professor, Infectious Diseases and Microbiology, The University of Queensland
-
Associate Professor and Chief Health Officer - COVID and Health Emergencies, Burnet Institute
-
Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle